Insider Selling: Outset Medical (NASDAQ:OM) CEO Sells $11,259.35 in Stock

Outset Medical, Inc. (NASDAQ:OM) CEO Leslie Trigg sold 3,361 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $3.35, for a total transaction of $11,259.35. Following the completion of the transaction, the chief executive officer owned 102,342 shares in the company, valued at $342,845.70. This represents a 3.18% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Leslie Trigg also recently made the following trade(s):

• On Wednesday, January 21st, Leslie Trigg sold 2,120 shares of Outset Medical stock. The stock was sold at an average price of $5.05, for a total transaction of $10,706.00.
• On Tuesday, January 20th, Leslie Trigg sold 11,794 shares of Outset Medical stock. The shares were sold at an average price of $5.12, for a total transaction of $60,385.28.
• On Wednesday, January 7th, Leslie Trigg sold 1,795 shares of Outset Medical stock. The stock was sold at an average price of $4.27, for a total transaction of $7,664.65.

Outset Medical Price Performance

Shares of NASDAQ:OM opened at $3.53 on Friday. The stock’s 50-day moving average is $4.33 and its 200 day moving average is $8.95. The company has a market cap of $64.63 million, a PE ratio of -0.52 and a beta of 2.08. The company has a debt-to-equity ratio of 0.76, a current ratio of 6.67 and a quick ratio of 5.77. Outset Medical, Inc. has a 1 year low of $3.10 and a 1 year high of $21.98.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the stock. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $7.00 price target on shares of Outset Medical in a report on Wednesday, December 17th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Outset Medical in a research report on Monday, December 29th. Stifel Nicolaus lowered their price objective on shares of Outset Medical from $14.00 to $8.00 and set a “buy” rating for the company in a report on Wednesday, January 7th. BTIG Research decreased their target price on Outset Medical from $17.00 to $15.00 and set a “buy” rating for the company in a research report on Thursday, February 12th. Finally, Wall Street Zen lowered Outset Medical from a “hold” rating to a “sell” rating in a research report on Sunday, February 8th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $10.00.

Hedge Funds Weigh In On Outset Medical

A number of hedge funds have recently bought and sold shares of OM. Los Angeles Capital Management LLC bought a new stake in Outset Medical during the 4th quarter valued at about $29,000. Legal & General Group Plc purchased a new stake in shares of Outset Medical during the second quarter valued at approximately $34,000. Ameritas Investment Partners Inc. purchased a new stake in shares of Outset Medical during the second quarter valued at approximately $35,000. BNP Paribas Financial Markets increased its position in shares of Outset Medical by 7,013.8% during the second quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company’s stock valued at $40,000 after acquiring an additional 2,034 shares in the last quarter. Finally, HRT Financial LP purchased a new position in Outset Medical in the 4th quarter worth approximately $58,000.

About Outset Medical

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.